Cutia Therapeutics Advances CU-30101 Cream

Cutia Therapeutics (HK:2487) has released an update.

Cutia Therapeutics has announced the acceptance of its drug marketing authorization application for CU-30101, a topical anesthesia cream, by the National Medical Products Administration of China. This follows the successful Phase III clinical trial mentioned in a previous announcement. However, the company cautions shareholders and potential investors that there is no guarantee CU-30101 will be successfully marketed.

For further insights into HK:2487 stock, check out TipRanks’ Stock Analysis page.